Results 201 to 210 of about 9,193,993 (329)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Disruption of protein-protein interaction hotspots in the C-terminal domain of MLH1 confers mismatch repair deficiency. [PDF]

NAR Cancer
Fishwick KM, Gomez Vieito D, Greco G, Collotta G, Gatti M, Kulik AA, Guérois R, Corbeski I, Phadte AS, Senoussi I, Cejka P, Pluciennik A, Porro A, Sartori AA.   +13 more
europepmc   +1 more source

the-alpha-fetoprotein-receptor-binding-fragment-localization-of-third-domain-interaction-sites-of-dna-repair-proteins/# [PDF]

, 2017
Gerald J. Mizejewski, G Mizejewski, G Mizejewski, G Mizejewski, G Mizejewski, S Naidu, M Peterson, B Spear, F Herve, K Rajkowski, M Martin, P Dessen, M Li, P Li, S He, G Du, G Li, G Mizejewski, G Mizejewski, A Atemezem, E Mbemba, R Marfaing, J Vaysse, M Pontet, G Mizejewski, M Li, H Li, C Li, S Zhou, G Mizejewski, G Posypanova, N Gorokhovets, V Makarov, L Savvateeva, G Posypanova, V Makarov, M Savvateeva, A Bereznikova, N Yabbarov, G Posypanova, E Vorontsov, S Obydenny, O Sharapova, N Pozdnykova, D Laurinavichyute, M Yurkova, O Sharapova, M Iurkova, S Andronova, A Fedorov, O Sharapova, N Pozdniakova, D Laurinavichiute, M Iurkova, D Carter, X He, S Munson, P Twigg, K Gernert, R Osmond, S Das, M Crouch, J Gerald, Mizejewski, G Mizejewski, J Duncan, J Reeves, T Cooke, B Friedenson, K Yoshida, Y Miki, N Lakhi, G Mizejewski, L Starita, J Parvin, Y Wang, D Cortez, P Yazdi, N Neff, J Paterson, B Henderson, B Xia, Q Sheng, K Nakanishi, A Ohashi, J Wu, R Buisson, A Dion-Cote, Y Coulombe, H Launay, N Kondo, A Takahashi, E Mori, T Noda, M O'driscoll, V Ruiz-Perez, C Woods, P Jeggo, A Smogorzewska, S Matsuoka   +99 more
openalex   +1 more source

Kinetics and equilibria of the interactions of heme proteins with copper (II) complexes

, 2021
Mary Ann Augustin
openalex   +2 more sources

Protein-protein interaction modulators: advances, successes and remaining challenges

Biophysical Reviews, 2019
Lloyd Mabonga, A. Kappo
semanticscholar   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Targeting the protein-protein interaction between the CDC37 cochaperone and client kinases by an allosteric RAF dimer breaker. [PDF]

J Biol Chem
Yu A, Banerjee S, Malasani S, Towolawi B, Liu Z, Wang Z.   +5 more
europepmc   +1 more source

Development of a Split Esterase 1 for Protein-Protein 2 Interaction Dependent Small Molecule Activation [PDF]

, 2019
Krysten A. Jones, Kaitlin Kentala, Michael Beck, Weiwei An, Alexander R. Lippert, Jared C. Lewis, Bryan C. Dickinson   +6 more
openalex   +1 more source

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son, Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha‐Coello, Yi Liao, Eric B. Haura, Alexander Drilon, John M. Koomen, Emiliano Cocco, Uwe Rix   +13 more
wiley   +1 more source